Pfizer Inc (PFE.N)
42.14USD
10:16pm IST
$-0.46 (-1.08%)
$42.60
$42.49
$42.52
$42.00
1,007,585
8,023,919
$46.46
$34.32
About
Overall
| Beta: | 0.99 |
| Market Cap(Mil.): | $214,682.30 |
| Shares Outstanding(Mil.): | 5,955.13 |
| Dividend: | 0.32 |
| Yield (%): | 3.55 |
Financials
| PFE.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 26.26 | 30.48 | 33.70 |
| EPS (TTM): | 1.37 | -- | -- |
| ROI: | 6.00 | 14.95 | 14.45 |
| ROE: | 13.80 | 16.27 | 15.96 |
Pfizer-Lilly drug shown to help reduce back pain in late-stage trial
A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday.
UPDATE 1-Pfizer-Lilly drug shown to help reduce back pain in late-stage trial
Feb 19 A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday.
Higher dose of Pfizer-Lilly drug helps reduce back pain in study
Feb 19 Pfizer and Eli Lilly said on Tuesday that a higher dose of their non-opioid drug tanezumab succeeded in reducing chronic low back pain in patients in a late-stage clinical study.
Merck, Pfizer drug combo extends kidney cancer survival - study
A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.
Merck, Pfizer drug combo extends kidney cancer survival: study
A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.
Merck, Pfizer drug combo extends kidney cancer survival -study
Feb 16 A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.
Merck, Pfizer combo treatment boosts kidney cancer survival
NEW YORK Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.
Merck, Pfizer combo treatment boosts kidney cancer survival
NEW YORK Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.
Pfizer Japan recalls high blood pressure drug over cancer-causing impurity
TOKYO The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday.
Pfizer Japan recalls high blood pressure drug over cancer-causing impurity
TOKYO The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday.
Estimates